Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025

Reuters

08/29

Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025

Sinopharm Group Co. Ltd. has released its 2025 interim report highlighting the financial performance of its subsidiary, China National Accord Medicines Corporation Ltd. ("Sinopharm Accord"). The report details that for the six months ending 30 June 2025, Sinopharm Accord experienced a slight decrease in revenue, totaling 36.8 billion yuan, down 2.62% from the same period last year. The net profit attributable to shareholders of the listed company also saw a decline of 10.43%, amounting to 665.9 million yuan. Furthermore, net cash flow from operating activities dropped significantly by 98.38% compared to the previous year. Despite these decreases, Sinopharm Accord's total assets saw an increase of 6.04%, reaching over 50.4 billion yuan, with net assets attributable to shareholders rising by 2.64%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2563021321"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563021321\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563021321?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563021321","market":"nz","top_or_hot":-1,"title":"Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHTDF\">Sinopharm Group Co. Ltd.</a> has released its 2025 interim report highlighting the financial performance of its subsidiary, <a href=\"https://laohu8.com/S/000028\">China National Accord Medicines</a> Corporation Ltd. (\"Sinopharm Accord\"). The report details that for the six months ending 30 June 2025, Sinopharm Accord experienced a slight decrease in revenue, totaling 36.8 billion yuan, down 2.62% from the same period last year. The net profit attributable to shareholders of the listed company also saw a decline of 10.43%, amounting to 665.9 million yuan. Furthermore, net cash flow from operating activities dropped significantly by 98.38% compared to the previous year. Despite these decreases, Sinopharm Accord's total assets saw an increase of 6.04%, reaching over 50.4 billion yuan, with net assets attributable to shareholders rising by 2.64%.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinopharm Accord Reports Decline in Revenue and Profits for H1 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-08-29 21:54</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHTDF\">Sinopharm Group Co. Ltd.</a> has released its 2025 interim report highlighting the financial performance of its subsidiary, <a href=\"https://laohu8.com/S/000028\">China National Accord Medicines</a> Corporation Ltd. (\"Sinopharm Accord\"). The report details that for the six months ending 30 June 2025, Sinopharm Accord experienced a slight decrease in revenue, totaling 36.8 billion yuan, down 2.62% from the same period last year. The net profit attributable to shareholders of the listed company also saw a decline of 10.43%, amounting to 665.9 million yuan. Furthermore, net cash flow from operating activities dropped significantly by 98.38% compared to the previous year. Despite these decreases, Sinopharm Accord's total assets saw an increase of 6.04%, reaching over 50.4 billion yuan, with net assets attributable to shareholders rising by 2.64%.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01099","symbol_name":"國藥控股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL8P1dQ2:1","article_id":"2563021321","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563021321","pubTimestamp":1756475687,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sinopharm Group Co. Ltd. has released its 2025 interim report highlighting the financial performance of its subsidiary, China National Accord Medicines Corporation Ltd. . The report details that for the six months ending 30 June 2025, Sinopharm Accord experienced a slight decrease in revenue, totaling 36.8 billion yuan, down 2.62% from the same period last year. The net profit attributable to shareholders of the listed company also saw a decline of 10.43%, amounting to 665.9 million yuan. Furthermore, net cash flow from operating activities dropped significantly by 98.38% compared to the previous year. Despite these decreases, Sinopharm Accord's total assets saw an increase of 6.04%, reaching over 50.4 billion yuan, with net assets attributable to shareholders rising by 2.64%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"01099":"国药控股","000028":"国药一致"},"translate_title":"国药一致报告2025年上半年收入和利润下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000028":0.9,"01099":0.9},"content_text":"Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025\n    \n\nSinopharm Group Co. Ltd. has released its 2025 interim report highlighting the financial performance of its subsidiary, China National Accord Medicines Corporation Ltd. (\"Sinopharm Accord\"). The report details that for the six months ending 30 June 2025, Sinopharm Accord experienced a slight decrease in revenue, totaling 36.8 billion yuan, down 2.62% from the same period last year. The net profit attributable to shareholders of the listed company also saw a decline of 10.43%, amounting to 665.9 million yuan. Furthermore, net cash flow from operating activities dropped significantly by 98.38% compared to the previous year. Despite these decreases, Sinopharm Accord's total assets saw an increase of 6.04%, reaching over 50.4 billion yuan, with net assets attributable to shareholders rising by 2.64%.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on August 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}